Endologix Inc., had revenue of $153.6 million in for 2015, an increase of four percent compared to the $147.6 million for the year ending in 2014, according to its recently released earnings. The Irvine, Calif.- based company said it earned $39.2 million in revenue in 4Q15, about a one percent increase over revenue in 4Q14. In 2015, the company significantly boosted its endovascular abdominal aortic aneurysm treatment options when it revealed it would merge with Trivascular Inc. in a transaction valued at $211 million. Shares of Endologix (NASDAQ:ELGX) were down .4 percent, trading at $7.50 early Tuesday.